Gautam George, MD
Pulmonary Disease · Cambridge, MANPI 1912252032
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Boehringer Ingelheim at 47.7% of the total. 2025 is the largest year on record at $18,664, 3.3 times the $5,644 reported in 2022. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $573.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$23K
- United Therapeutics Corporation$19K
- Chiesi USA, Inc.$6K
- GSK$170
- Genentech USA, Inc.$68
- AbbVie$43
- plus $103 from 4 others
Across 98 payments — averaging $7730.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$325K
- Roche Products Limited$220K
- Genentech, Inc.$132K
- Hoffmann-la Roche Limited$41K
- F. Hoffmann-la Roche AG$41K
What the payments were for
- Consulting fees$18,45038%
- Speaking & faculty fees$20,93043%
- Travel & lodging$6,72714%
- Food & beverage$2,0984%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 24 | $22,970 |
| United Therapeutics Corporation | 36 | $19,163 |
| Chiesi USA, Inc. | 7 | $5,688 |
| GSK | 8 | $170 |
| Genentech USA, Inc. | 3 | $68 |
| AbbVie | 1 | $43 |
| AstraZeneca | 2 | $37 |
| Amgen | 1 | $25 |
| Sanofi | 1 | $24 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYVASO$7,775
How this compares
$48,205 in reported general payments places this provider in the 90th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 88 | $1,124,051 |
| Tyvaso DpiTreprostinil | 17 | $387,817 |
| Dupixent PenDupilumab | 48 | $177,945 |
| Pirfenidone | 36 | $115,881 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 128 | $100,903 |
| Breo ElliptaFluticasone/Vilanterol | 62 | $28,590 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $21,709 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $14,806 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $13,924 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $7,002 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $5,894 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $5,665 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,637 |
| Mycophenolate Mofetil | 23 | $3,821 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 111 | $3,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $22,970 | $1,135,582112 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $170 | $144,299214 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $37 | $35,63377 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Cambridge
- Lakshmana SwamyCambridge$30K
- Yaron GoldmanWorcester$843K
- Sarah GrantBrookline$678K
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Fernando MartinezWorcester$375K
- Ana CojocaruFall River$364K
- Adnan MajidBoston$351K
- Adam SmithBurlington$296K
- Nicholas HillBoston$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.